Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
84.54(c) 85.42(c) 82.27(c) 82.9(c) 83.23 Last
3 217 154 886 532 1 069 576 881 614 215 302 Volume
+1.55% +1.04% -3.69% +0.77% +0.40% Change
More quotes
Financials (USD)
Sales 2020 2 533 M - -
Net income 2020 -340 M - -
Net cash position 2020 1 886 M - -
P/E ratio 2020 -52,9x
Yield 2020 -
Sales 2021 2 883 M - -
Net income 2021 617 M - -
Net cash position 2021 2 514 M - -
P/E ratio 2021 30,4x
Yield 2021 -
Capitalization 18 155 M 18 155 M -
EV / Sales 2020 6,42x
EV / Sales 2021 5,43x
Nbr of Employees 1 456
Free-Float 98,6%
More Financials
Company
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (82.2%); - royalties (14.2%); - income from research and cooperation agreements (3.6%). 
More about the company
Notations Surperformance© of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
All news about INCYTE CORPORATION
12:31pINCYTE : Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi®) Si..
BU
11/20ELI LILLY AND COMPANY : - Baricitinib Receives Emergency Use Authorization from ..
AQ
11/19ELI LILLY AND : Incyte Say FDA Grants EUA for Baricitinib
DJ
11/19INCYTE : Baricitinib Receives Emergency Use Authorization from the FDA for the T..
PR
11/12INCYTE : to Present at Upcoming Investor Conference
BU
11/11INCYTE : Xencor, MorphoSys and Incyte Enter into Global Development Collaboratio..
BU
11/09INCYTE : Data from Incyte's Oncology Portfolio Accepted for Presentation at the ..
BU
11/05Qualcomm, Upwork rise; Hanesbrands, Incyte fall
AQ
11/05Qualcomm, Upwork rise; Hanesbrands, Incyte fall
AQ
11/05INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
AQ
11/05INCYTE : 3Q Earnings Snapshot
AQ
11/05INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
AQ
11/05INCYTE : Reports 2020 Third Quarter Financial Results and Provides Updates on Ke..
BU
11/05INCYTE CORPORATION : 3rd quarter results
CO
11/04INCYTE : More than 40 Abstracts from Incyte's Oncology Portfolio Accepted for Pr..
BU
More news
News in other languages on INCYTE CORPORATION
11/12Eigenes Medikament bringt Morphosys kurz nach Start Millionenerlös
11/11Morphosys hat mit Monjuvi bereits mehr als vier Millionen Euro umgesetzt
11/05INCYTE : Plus de 40 abstracts du portefeuille d'oncologie d'Incyte sont acceptés..
11/05INCYTE : Mehr als 40 Abstracts aus dem Onkologieportfolio von Incyte zur Präsent..
10/29INCYTE : Zusammengefasste Ergebnisse der Incyte-Studien TRuE-AD1 und TRuE-AD2 zu..
More news
Analyst Recommendations on INCYTE CORPORATION
More recommendations
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 104,00 $
Last Close Price 82,90 $
Spread / Highest target 60,4%
Spread / Average Target 25,5%
Spread / Lowest Target 2,53%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Paul A. Friedman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-5.78%18 155
MODERNA, INC.705.88%62 229
LONZA GROUP AG52.83%45 010
CELLTRION, INC.109.94%42 993
SEAGEN INC.57.68%32 484
IQVIA HOLDINGS INC.8.49%32 139